Table 17Longitudinal Results of Self-Efficacy (n = 777)

Self-efficacyImpact estimate by model over time between wk 1 and mo 6 (95% CI)a
Specialized consultativeSpecialized longitudinalOncology embedded
Baseline to wk 1(Reference).019 (−0.086 to 0.124)−0.120** (−0.210 to .031)
Baseline to 3 mo(Reference).052 (−0.057 to 0.162)−0.011 (−0.104 to 0.082)
Baseline to 6 mo(Reference).045 (−0.070 to 0.162)0.029 (−0.068 to 0.129)

aModels control for age, gender, race, ethnicity, marital status, education, income, primary provider of survivorship care, and time since diagnosis. ***P < .001; and *P < .01.

**P < .05;

From: Evaluating Different Types of Cancer Survivorship Care

Cover of Evaluating Different Types of Cancer Survivorship Care
Evaluating Different Types of Cancer Survivorship Care [Internet].
Mead KH, Raskin S, Arem H, et al.
Copyright © 2019. George Washington University. All Rights Reserved.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License which permits noncommercial use and distribution provided the original author(s) and source are credited. (See https://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.